MAXCYTE, INC. — Investor Relations & Filings
MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Dr Richard Douglas Joins MaxCyte Board | 2018-02-13 | English | |
| Block listing Interim Review | 2018-02-01 | English | |
| Total Voting Rights | 2018-01-23 | English | |
| Total Voting Rights | 2018-01-23 | English | |
| Trading Update | 2018-01-22 | English | |
| Total Voting Rights | 2018-01-12 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2018
6 filings
| |||||
| 10487755 | Dr Richard Douglas Joins MaxCyte Board | 2018-02-13 | English | ||
| 10481090 | Block listing Interim Review | 2018-02-01 | English | ||
| 10471935 | Total Voting Rights | 2018-01-23 | English | ||
| 10471933 | Total Voting Rights | 2018-01-23 | English | ||
| 10470849 | Trading Update | 2018-01-22 | English | ||
| 10468914 | Total Voting Rights | 2018-01-12 | English | ||
|
2017
9 filings
| |||||
| 10465528 | Trading Update | 2017-07-12 | English | ||
| 10455111 | Research & Development Agreement with NIAID | 2017-06-06 | English | ||
| 10453524 | Total Voting Rights | 2017-05-31 | English | ||
| 10448007 | Block Listing Application | 2017-05-02 | English | ||
| 10446834 | Holding(s) in Company | 2017-04-25 | English | ||
| 10446655 | Presentation of Positive Preclinical Data | 2017-04-25 | English | ||
| 10446125 | Result of Special Meeting and Issue of Equity | 2017-04-20 | English | ||
| 10445575 | Notice of AGM and 2016 Annual Report and Accounts | 2017-04-13 | English | ||
| 10443483 | Results of Placing | 2017-03-31 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
MAXCYTE, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/10520/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=10520 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=10520 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=10520 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 10520}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MAXCYTE, INC. (id: 10520)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.